Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

X. Hou, M.-Z. Yang,J.-B. Li,Z.-H. Tan, H. Long,J.-H. Fu,L.-J. Zhang, P. Lin,H.-X. Yang

ESMO Open（2022）

引用 2|浏览18

暂无评分

摘要

•ACT could not improve long-term survival in pT2N0M0 NSCLC in general.•ACT could only improve OS and DFS in pT2N0M0 NSCLC >4 cm.•ACT could not improve CSS in any subgroup of pT2N0M0 NSCLC.•For patients with other high-risk factors, ACT failed to improve long-term survival.

查看译文

关键词

non-small cell lung cancer,T2N0M0,adjuvant chemotherapy,survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要